Medical/Pharmaceuticals

Brii Biosciences Announces the Completion of Enrollment in the Phase 3 National Institutes of Health (NIH) ACTIV-2 Trial, Evaluating the BRII-196 and BRII-198 Monoclonal Neutralizing Antibody Combination for the Treatment of COVID-19

846 outpatients at high risk of clinical progression have been enrolled in the ACTIV-2 phase 2/3 clinical study, from sites inthe United States, Brazil, South Africa, Mexico and Argentina. The participants are being evaluated for the combined endpoint of hospitalizations and death relative ...

2021-08-05 22:46 5906

ArisGlobal Lauded by Frost & Sullivan for Enabling Life Sciences Companies to Accelerate R&D with Its LifeSphere® Platform

LifeSphere® ably supports clients by expediting decision-making, maintaining compliance, and streamlining collaborations among cross-functional teams SANTA CLARA, Calif., Aug. 5, 2021 /PRNewswire/ -- Based on its recent analysis of the North American clinical development and pharmacovigilance so...

2021-08-05 21:55 3029

China Pharma's Candesartan Hypertension Product Passes Bioequivalence Tests and the Company Plans to Apply for NMPA Approval

HAIKOU, China, Aug. 5, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that its Candesartan hypertension product passed key bioequivalence tests. The Company plans to use the result...

2021-08-05 21:00 27284

Berry Oncology Completes Series B1 Funding, Attracting Most Venture Capital to Date in Early Cancer Screening Sector

BEIJING, Aug. 5, 2021 /PRNewswire/ -- Berry Oncology Corporation, a member company ofChina's leading early cancer screening firm Berry Genomics, yesterday on its 4th anniversary, announced the completion of a US$99.15 million Series B1 financing round. This brings the total capital raised by the ...

2021-08-05 21:00 2587

Insilico Medicine and Usynova Announce Strategic Partnership on Accelerating R&D of Small Molecule Innovative Drugs with AI

SHANGHAI, Aug. 5, 2021 /PRNewswire/ -- Insilico Medicine, an industry leader in end-to-end artificial intelligence for target discovery, small molecule chemistry, and clinical development, and Usynova announced to reach strategic cooperation in advancing the development of novel therapies.

2021-08-05 18:23 4124

Pharmaxis Cancer Drug Decreases Tumour Burden in Pre Clinical Liver Cancer Model

SYDNEY, Aug. 5, 2021 /PRNewswire/ -- Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced the first public presentation of data from a preclinical study of PXS-5505 in the liver cancer, cholangiocarcinoma (CCA) at the Americas Hepato-Pancreato-Biliary Association (AHBP...

2021-08-05 18:00 1997

CUHK Discovers Children with Autism Have Delayed Gut Microbiome Maturity and Identifies Faecal Bacterial Markers for Autism

HONG KONG, Aug. 5, 2021 /PRNewswire/ -- The Faculty of Medicine of The Chinese University of Hong Kong (CU Medicine) reports a ground breaking discovery that children with autism spectrum disorder (autism) showed delayed gut microbiome maturity compared with typically developing children. They ha...

2021-08-05 16:40 5323

KYOWA Pharmaceutical Industry Co. Ltd. Partners with Bora Pharmaceuticals to Manufacture Generic Product for Filing in Japan

TAIPEI, Aug. 5, 2021 /PRNewswire/ -- KYOWA Pharmaceutical Industry Co. Ltd., a premier Japanese pharmaceutical company, has contracted with Bora Pharmaceutical Laboratories Inc. (Zhunan), a division of Bora Pharmaceuticals for the manufacturing of generic product for filing inJapan. KYOWA will be...

2021-08-05 14:50 2735

Inmagene and Kissei Enter into an Exclusive License Agreement for Fostamatinib in China

SHANGHAI and SAN DIEGO and NAGANO, Japan, Aug. 5, 2021 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene") and Kissei Pharmaceutical Co., Ltd. ("Kissei") announced today that they have entered into an exclusive license agreement for the development and commercialization of fostamatinib in ma...

2021-08-05 14:00 3989

Everest Medicines Announces Approval of Clinical Trial Application by China NMPA for Phase 3 Trial of Xerava(TM) for Community-Acquired Bacterial Pneumonia

SHANGHAI, Aug. 5, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inGreater Ch...

2021-08-05 13:12 5218

Chinese Multinational Technology Company, HUAWEI, Aligns With Singapore-Based Healthtech Start-up PLANO to Tackle the Global Problem of Myopia

SINGAPORE, Aug. 5, 2021 /PRNewswire/ -- Shenzhen, Guangdong, China, and Singapore – Huawei Technologies Co. Ltd. (hereinafter, Huawei) and Plano Pte. Ltd. (hereinafter, Plano) today announced their partnership to address the global problem of myopia. Through this partnership, Huawei and Plano wil...

2021-08-05 10:00 3035

Over 3,000 units of HFNC delivered to Poland and Peru, Micomme Medical helps the world fight against COVID-19 pandemic

CHANGSHA, China, Aug. 5, 2021 /PRNewswire/ -- Recently, Micomme has associated with Polish and Peruvian partners to accomplish the government centralized purchase of 1,600 and 1,500 units of HFNC respectively. Both purchases are strategic material reserves of the local governments. The global pa...

2021-08-05 09:55 3162

A New Approach to Dealing With Shortsightedness (Myopia) & Dry Eye in Children

PETALING JAYA, Malaysia  , Aug. 5, 2021 /PRNewswire/ -- VISTA Eye Specialist (VISTA) is one of the first among eyecare professionals inMalaysia to adopt an all-in-one diagnostic tool - the MYAH by Topcon, that offers the essential tools for shortsightedness (myopia) management and also as an evol...

2021-08-05 08:00 5857

Wealth Dynamix Wins 'XCelent Functionality Award' in New Wealth Management CRM Report

LONDON, Aug. 5, 2021 /PRNewswire/ -- Wealth Dynamix , a global leader in Client Lifecycle Management (CLM) solutions, today announced its selection by global research and advisory firm Celent as a winner of the XCelent Functionality Award. The award was revealed i...

2021-08-05 06:58 3998

ABL Bio Receives IND Approval for Phase 1 Clinical Trial of ABL501, an anti-LAG-3/PD-L1 Bispecific Antibody

* South Korea's MFDS clears IND application for a Phase 1 study evaluating the safety and preliminary efficacy of ABL501 as a monotherapy for solid tumor treatment * ABL's third IND this year for bispecific antibody therapeutics SEONGNAM, South Korea, Aug. 4, 2021 /PRNewswire/ -- ABL Bio, Inc...

2021-08-04 21:30 2691

Novavax and European Commission Finalize Advance Purchase Agreement for up to 200 million doses of COVID-19 Vaccine

GAITHERSBURG, Md., Aug. 4, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has reached an agreement with the European Commission (EC) for the purchase of up to 200 million doses...

2021-08-04 21:10 10483

Alterity Therapeutics Announces New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases including Alzheimer's and Parkinson's

MELBOURNE, Australia, Aug. 4, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced the United States Patent and Trademark Of...

2021-08-04 20:39 25531

New Global Study Reveals Post-Pandemic Consumer Behaviours, Expectations and Concerns

Enduring appeal of in-store shopping, and continued fears about data privacy among surprising findings in "Future of Commerce |The Why Behind the Buy" LONDON, Aug. 4, 2021 /PRNewswire/ -- As the marketing industry worldwide continues its efforts to both map and navigate the post-pandemic commerce...

2021-08-04 19:00 1836

MitraClip implant at Apollo Hospitals saves 41-year-old farmer who waited 91 days for heart transplant

"1 out of 5 patients may get off the heart transplant list if they have access to this therapy" - says Dr. Sai Satish CHENNAI, India, Aug. 4, 2021 /PRNewswire/ -- Apollo Hospitals, Asia's foremost and most trusted healthcare group, today announced a successful MitraClip implant on a 41-year-old ...

2021-08-04 18:50 3334

Insilico Medicine Announces the Preclinical Candidate for Kidney Fibrosis Discovered Using End-to-End Artificial Intelligence Engine

HONG KONG, Aug. 4, 2021 /PRNewswire/ -- Insilico Medicine, a global company specializing in the applications of the next-generation machine learning technologies for drug discovery and development, announced today that its AI-powered drug discovery platform had delivered the preclinical candidate...

2021-08-04 18:11 3265
1 ... 618619620621622623624 ... 650